Referências
1- Eguia, A.; Bagán-Debón, L.; Cardona, F. Review and update on drugs related to the development of osteonecrosis of the jaw.Med. Oral Patología Oral y Cirugia Bucal 2020, 25, e71–e83. [CrossRef] [PubMed].
2- https://www.who.int/pt/about, https://www.osteoporosis.foundation
3- Sacco R, Woolley J, Patel G, Calasans-Maia MD, Yates J. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy? Br J Oral Maxillofac Surg. 2022 Feb;60(2):e216-e230. doi: 10.1016/j.bjoms.2021.03.006. Epub 2021 Mar 24. PMID: 35115201.
4- Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3. PMID: 35866376; PMCID: PMC9309005.
5- Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. Journal of Oral and Maxillofacial Surgery [Internet]. 2022;80(5):920–43.
6- Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral. Maxillofac. Surg. 2014, 72, 1938–1956].
7- Shibahara T. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone. Tohoku J Exp Med. 2019 Feb;247(2):75-86. doi: 10.1620/tjem.247.75. PMID: 30713280.
8- Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005 Jul 1;104(1):83-93. doi: 10.1002/cncr.21130. PMID: 15929121.
9- Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg. 2008 Jul;66(7):1516-7. doi: 10.1016/j.joms.2008.02.012. PMID: 18571043.
10- Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug;104(2):249-58. doi: 10.1016/j.tripleo.2007.01.040.
11- Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jáws. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):75-84. doi: 10.1016/j.joms.2008.12.002. PMID: 19371818.
12- Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):75-84. doi: 10.1016/j.joms.2008.12.002. PMID: 19371818.
13- Meza Maurício J, Miranda TS, Almeida ML, Silva HD, Figueiredo LC, Duarte PM: An umbrella review on the effects of diabetes on implant failure and peri-implant diseases. Braz Oral Res. 2019, 33:e070.
14- Giovannacci I, Meleti M, Manfredi M, Mortellaro C, Greco Lucchina A, Bonanini M, Vescovi P. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? J Craniofac Surg. 2016 May;27(3):697-701. doi: 10.1097/SCS.0000000000002564. PMID: 27092912.
15- Granate-Marques A, Polis-Yanes C, Seminario-Amez M, Jané-Salas E, López-López J. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review. Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24(2):e195-e203. doi: 10.4317/medoral.22691. PMID: 30818312; PMCID: PMC6441601.
16- Mendes V, Dos Santos GO, Calasans-Maia MD, Granjeiro JM, Moraschini V. Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence. Int J Oral Maxillofac Surg. 2019 Mar;48(3):373-381. doi: 10.1016/j.ijom.2018.09.006. Epub 2018 Oct 9. PMID: 30314708.////// Ryu JI, Kim HY, Kwon YD. Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study. Clin Oral Implants Res. 2021 Apr;32(4):437-447. doi: 10.1111/clr.13713.
17- Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009 Jan;20(1):117-20. doi: 10.1093/annonc/mdn554.
18- Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410. doi: 10.1016/j.joms.2007.08.003. PMID: 18022461.
19- Awad ME, Sun C, Jernigan J, Elsalanty M. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis. J Am Dent Assoc. 2019 Aug;150(8):664-675.e8. doi: 10.1016/j.adaj.2019.03.006.
20- Otto, S, Pautke, C. Treatment of medication-related osteonecrosis of the jaw. Medication Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab and New Agents. Springer-Verlog Berlin Heidelberg. 2015:79-92.
21- Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;128(5):491-7. e2.
22- Momesso GAC, Lemos CAA, Santiago-J.nior JF, Faverani LP, Pellizzer EP. Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis. Oral Maxillofac Surg 2020;24(2):133-44.
23- Ervolino E, Statkievicz C, Toro LF, de Mello-Neto JM, Cavazana TP, Issa JPM et al. Antimicrobial photodynamic therapy improves the alveolar repair process and prevents the occurrence of osteonecrosis of the jaws after tooth extraction in senile rats treated with zoledronate. Bone 2019;120:101-13.
24- Cano-Durán JA, Peña-Cardelles JF, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017 Aug 1;9(8):e1051-e1059. doi: 10.4317/jced.54154. PMID: 28936298; PMCID: PMC5601107.
